Search Results - "Ling, Alexander L."

Oncolytic immunoactivation associates with survival in a glioblastoma clinical trial by Ling, Alexander L, Chiocca, E Antonio

Get full text

Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling? by Chen, Ethan, Ling, Alexander L, Reardon, David A, Chiocca, E Antonio

“…Abstract Glioblastoma (GBM)’s median overall survival is almost 21 months. Six phase 3 immunotherapy clinical trials have recently been published, yet 5/6 did…”
Get full text

Clinical trial links oncolytic immunoactivation to survival in glioblastoma by Ling, Alexander L., Solomon, Isaac H., Landivar, Ana Montalvo, Nakashima, Hiroshi, Woods, Jared K., Santos, Andres, Masud, Nafisa, Fell, Geoffrey, Mo, Xiaokui, Yilmaz, Ayse S., Grant, James, Zhang, Abigail, Bernstock, Joshua D., Torio, Erickson, Ito, Hirotaka, Liu, Junfeng, Shono, Naoyuki, Nowicki, Michal O., Triggs, Daniel, Halloran, Patrick, Piranlioglu, Raziye, Soni, Himanshu, Stopa, Brittany, Bi, Wenya Linda, Peruzzi, Pierpaolo, Chen, Ethan, Malinowski, Seth W., Prabhu, Michael C., Zeng, Yu, Carlisle, Anne, Rodig, Scott J., Wen, Patrick Y., Lee, Eudocia Quant, Nayak, Lakshmi, Chukwueke, Ugonma, Gonzalez Castro, L. Nicolas, Dumont, Sydney D., Batchelor, Tracy, Kittelberger, Kara, Tikhonova, Ekaterina, Miheecheva, Natalia, Tabakov, Dmitry, Shin, Nara, Gorbacheva, Alisa, Shumskiy, Artemy, Frenkel, Felix, Aguilar-Cordova, Estuardo, Aguilar, Laura K., Krisky, David, Wechuck, James, Manzanera, Andrea, Matheny, Chris, Tak, Paul P., Barone, Francesca, Kovarsky, Daniel, Tirosh, Itay, Suvà, Mario L., Wucherpfennig, Kai W., Ligon, Keith, Reardon, David A., Chiocca, E. Antonio

“…Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent…”
Get full text

Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint Inhibitors by Toker, Joseph, Iorgulescu, J Bryan, Ling, Alexander L, Villa, Genaro R, Gadet, Josephina A M A, Parida, Laxmi, Getz, Gad, Wu, Catherine J, Reardon, David A, Chiocca, E Antonio, Mineo, Marco

“…mAbs targeting the PD-1/PD-L1 immune checkpoint are powerful tools to improve the survival of patients with cancer. Understanding the molecular basis of…”
Get full text

Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling by Zhang, Weijie, Lee, Adam M, Jena, Sampreeti, Huang, Yingbo, Ho, Yeung, Tietz, Kiel T, Miller, Conor R, Su, Mei-Chi, Mentzer, Joshua, Ling, Alexander L, Li, Yingming, Dehm, Scott M, Huang, R Stephanie

“…Prostate cancer (PC) is the most frequently diagnosed malignancy and a leading cause of cancer deaths in US men. Many PC cases metastasize and develop…”
Get full text

PPRX-1701, a nanoparticle formulation of 6′-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models by Zdioruk, Mykola, Jimenez-Macias, Jorge-Luis, Nowicki, Michal Oskar, Manz, Katherine E., Pennell, Kurt D., Koch, Marilin S., Finkelberg, Tomer, Wu, Bin, Boucher, Paul, Takeda, Yuji, Li, Weiyi, Piranlioglu, Raziye, Ling, Alexander L., Chiocca, E. Antonio, Lawler, Sean E.

“…Derivatives of the Chinese traditional medicine indirubin have shown potential for the treatment of cancer through a range of mechanisms. This study…”
Get full text